RecruitingPneumococcal VaccineEsophageal CancerLymphopenia

Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

To learn how radiation treatment may affect your responses to vaccines against pneumonia.

Sponsor: M.D. Anderson Cancer Center

✓ 1. Group 1A
✓ a. Patients currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with protons.
✓ 2. Group 1B
✓ a. Patients currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with intensity-modulated radiation therapy (IMRT)
✓ 3. Group 2A
✓ a. Patients currently receiving, planning to receive, or recently completed definitive proton therapy for unresectable liver cancer.
✓ 4. Group 2B
✓ a. Patients currently receiving, planning to receive, or recently completed definitive IMRT for unresectable liver cancer.

✕ Patients with compromised immunologic responses due to an uncontrolled intercurrent immunodeficiency (e.g., Human immunodeficiency virus (HIV), X-linked agammaglobulinemia) or previous or current immune suppressive therapy
✕ a. Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
✕ Patients receiving intravenous immunoglobulin (IVIG) during the study or in the three months prior to study enrollment.
✕ Patients with psychiatric illness/social situations that would limit compliance with study requirements.
✕ Individuals with previous pneumococcal vaccination in the last 5 years.
✕ Individuals with severe allergy to any of the vaccine components

Houston

Source: ClinicalTrials.gov · NCT06181656 · last updated 2026-05-20